CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


CytoSorb 300 mL deviceWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug833 Electrocardiogram, telemetry, echocardiogram, laboratory values Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D002318 Cardiovascular Diseases NIH 0.21

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0001626 Abnormality of the cardiovascular system HPO 0.21

There is one clinical trial.

Clinical Trials


1 Registry of CytoSorb Therapy in COVID-19 ICU Patients (CTC REGISTRY): Registry of Patient-level Clinical Data on CytoSorb Hemoadsorption Provided Via Integration of the CytoSorb Device Into Extracorporeal Membrane Oxygenation (ECMO), Continuous Renal Replacement Therapy (CRRT), or Hemoperfusion Extracorporeal Circuits in COVID-19 ICU Patients

The CTC Registry collects patient-level clinical data on CytoSorb hemoadsorption provided to COVID-19 ICU patients via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits under the FDA Emergency Use Authorization for this CytoSorb device use. The intent of the registry is to gain understanding on how CytoSorb hemoadsorption provides clinical benefit to COVID-19 ICU patients.

NCT04391920 COVID-19 Device: CytoSorb 300 mL device

Primary Outcomes

Measure: ICU mortality

Time: From the date of start of CytoSorb use until the date of ICU discharge or date of death, whichever comes first, assessed up to 1 year

Secondary Outcomes

Measure: Duration of ECMO after start of CytoSorb

Time: From the date of start of CytoSorb use until the date of cessation of ECMO or date of death, which ever comes first, assessed up to 1 year

Measure: Duration of mechanical ventilatory support after start of CytoSorb

Time: From the date of start of CytoSorb use until the date of cessation of mechanical ventilatory support or date of death, which ever comes first, assessed up to 1 year

Measure: Duration of pharmacologic hemodynamic support after start of CytoSorb

Time: From the date of start of CytoSorb use until the date of cessation of pharmacologic hemodynamic support or date of death, which ever comes first, assessed up to 1 year

Measure: Change in serum concentrations of inflammatory biomarkers after start of CytoSorb

Time: From the day before start of CytoSorb use until the day after cessation of CytoSorb use


No related HPO nodes (Using clinical trials)